Korro Bio Inc
KRRO
View Detailed Chart
8.120USD
-0.290-3.45%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
76.31MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.45%
5 Days
+3.05%
1 Month
+47.10%
6 Months
-32.50%
Year to Date
-78.67%
1 Year
-79.70%
View Detailed Chart
TradingKey Stock Score of Korro Bio Inc
Currency: USD Updated: 2025-12-26Key Insights
Korro Bio Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered undervalued, ranking 107/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 45.00.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Korro Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Hold
Current Rating
45.000
Target Price
+496.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Korro Bio Inc Highlights
StrengthsRisks
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.27M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.27M.
Overvalued
The company’s latest PE is -0.86, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.33M shares, decreasing 10.31% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 679.00 shares of this stock.
Korro Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Korro Bio Inc Info
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Ticker SymbolKRRO
CompanyKorro Bio Inc
CEODr. Ram Aiyar, Ph.D.
Websitehttps://www.korrobio.com/
FAQs
What is the current price of Korro Bio Inc (KRRO)?
The current price of Korro Bio Inc (KRRO) is 8.120.
What is the symbol of Korro Bio Inc?
The ticker symbol of Korro Bio Inc is KRRO.
What is the 52-week high of Korro Bio Inc?
The 52-week high of Korro Bio Inc is 55.890.
What is the 52-week low of Korro Bio Inc?
The 52-week low of Korro Bio Inc is 5.204.
What is the market capitalization of Korro Bio Inc?
The market capitalization of Korro Bio Inc is 76.31M.
What is the net income of Korro Bio Inc?
The net income of Korro Bio Inc is -83.58M.
Is Korro Bio Inc (KRRO) currently rated as Buy, Hold, or Sell?
According to analysts, Korro Bio Inc (KRRO) has an overall rating of Hold, with a price target of 45.000.
What is the Earnings Per Share (EPS TTM) of Korro Bio Inc (KRRO)?
The Earnings Per Share (EPS TTM) of Korro Bio Inc (KRRO) is -9.417.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
